Summit Therapeutics SMMT Research collaboration agreement — Revenue
Discontinued — last reported Q4 '20
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Summit Therapeutics’s 10-K, filed March 31, 2021, on SEC EDGAR. View the filing →
Questions, answered.
- What does research collaboration agreement — revenue mean?
- Revenue earned from partnering with other companies to jointly research and develop new drug candidates.
- How do you interpret research collaboration agreement — revenue?
- An increase indicates successful execution of partnership agreements and achievement of development milestones, while a decrease may suggest a lack of new collaborations or delays in reaching research targets.
- How does research collaboration agreement — revenue compare across companies?
- Common in biopharmaceutical firms, often compared against 'Collaboration Revenue' or 'License and Milestone Revenue' reported by peers in the drug development sector.